Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference Trevo® Pro System Restored 55% of Patients who Suffered a Severe Acute Ischemic Stroke to a Good Functional Outcome
KALAMAZOO, Mich., Feb. 2, 2012 /PRNewswire/ -- On February 2, at the Late-Breaking Science Session at the International Stroke Conference, Stryker announced the results of the TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke). This was one of the first prospective, multi-center clinical studies of clot-removing stent retriever technology. Sixty patients were enrolled by seven leading stroke centers in Europe.
The TREVO Study was designed to assess the ability of the Trevo® System to remove the blood clots that cause strokes and to restore blood flow to the brain. Revascularization was measured by an independent core lab.
The results were presented at the International Stroke Conference in New Orleans, LA by Professor Nils Wahlgren, co-Principal Investigator of the Study and Professor of Neurology at Karolinska University Hospital, Solna, Sweden. The results demonstrated high revascularization rates of 91.7% of patients. 46% of patients achieved a good outcome in just seven days and at 90 days, the good outcomes rate increased to 55%. These patients with good outcomes were functionally independent (modified Rankin score of 2 or less). A low symptomatic intracranial hemorrhage rate of 5% was also reported.
Professor Wahlgren commented: "The TREVO Study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo System. The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes that can be achieved for these patients."
Clinical evidence remains key for wider adoption of interventional, device-based therapies for the treatment of Acute Ischemic Stroke. The prospective design and rigorous conduct of the TREVO Study underscores Stryker's commitment to building robust evidence to support the adoption of important technologies like the Trevo System by physicians for their stroke patients.
Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.
Vice President, Public Affairs